Adrenocorticotropic Hormone (Acth) and Cortisone in Ophthalmology

Scheie, Harold G.; Tyner, George S.; Buesseler, John A.; Alfano, Joseph E.

doi:10.1001/archopht.1951.01700010307005

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1951

2011

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 34 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corticosteroids for the treatment of ocular disease was first described in the early 1950s. [3][4][5][6][7][8] Since that time, the goal of delivering therapeutic levels of corticosteroid to the eye while minimizing systemic exposure has become increasingly achievable. Pharmacokinetic limitations often render topical delivery inadequate for posterior segment diseases, 9,10 whereas subconjunctival, peribulbar, and intravitreal injections typically produce concentrations that are more effective, albeit short-lived and associated with significant side effects.…”

Section: Introductionmentioning

confidence: 99%

The dexamethasone drug delivery system: Indications and evidence

2011

View full text Add to dashboard Cite

The dexamethasone DDS is one of the most recent additions to the armamentarium against macular edema, and is intriguing for its potency, dose consistency, potential for extended duration of action, and favorable safety profile. Early evidence shows clinical utility for several conditions, the most well established being for macular edema associated with RVO. Future studies and, in particular, head-to-head comparisons with other treatment modalities will elucidate the precise role for the dexamethasone DDS in clinical practice.

show abstract